Skip to content

Evaluate the Predictive Impact of the MEESSI Score

Evaluate the Predictive Impact of the Meessi MEESSI Score for the Risk Stratification of Patients Admitted for Acute Heart Failure in Emergency Department

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05340972
Acronym
MEESSI
Enrollment
1500
Registered
2022-04-22
Start date
2009-01-15
Completion date
2023-05-30
Last updated
2023-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergencies, Heart Diseases

Keywords

MEESSI score, ACUTE HEART FAILURE

Brief summary

Our primary purpose is to assess MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department. European Society of Cardiology recommend risk stratification for patients with AHF.

Detailed description

Improved risk stratification of acute heart failure (AHF) in the emergency department (ED) may help physicians' decisions regarding patient admission or early discharge disposition. The MEESSI-AHF (Multiple Estimation of risk based on the Emergency department Spanish Score In patients with AHF) score was developed to predict 30-day mortality in patients presenting with AHF EDs in Spain. Whether it performs well in other countries is unknown. The MEESSI-AHF risk model includes 13 variables readily available on arrival to Emergency Department. The 40% of patients classified as LOW RISK (30-day mortality: \<2%) should be considered as potential candidates to be early discharged from Emergency Department without admission after adequate response to initial treatment. The 10% of patients classified as VERY HIGH RISK (30-day mortality: \>2%) may clearly benefit from hospital admission. Objective: To externally validate the MEESSI-AHF score in another country.

Interventions

DIAGNOSTIC_TESTMEESSI score

The score aimed to predict the AHF patient's future in the month following management for ED

Sponsors

University of Monastir
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* Major patient * Patient admitted to emergencies with final diagnosis of AHF according to the opinion of two emergency experts after consulting the data from the clinical examination, cardiac echocardiography, and BNP level. * Subject who accept to participate in the research

Exclusion criteria

* Patient who refuse to participate in the study * Patient with coronary syndrome with ST segment elevation * Other causes of dyspnea * Impossibility of giving the patient informed information * Pregnant woman

Design outcomes

Primary

MeasureTime frameDescription
MEESSI score30 dayspredict the AHF patient's future in the month following management in ED with The MEESSI (Multiple Estimation of risk based on the Emergency department Spanish Score In patients with AHF).The MEESSI-AHF risk model includes 13 variables readily available on arrival to Emergency Department. The 40% of patients classified as LOW RISK (30-day mortality: \<2%) should be considered as potential candidates to be early discharged from Emergency Department without admission after adequate response to initial treatment. The 10% of patients classified as VERY HIGH RISK (30-day mortality: \>2%) may clearly benefit from hospital admission.

Secondary

MeasureTime frameDescription
Re-admission rate [ Time Frame: 30 days ]30 days30-day re-admission rate compared between the 4 risk categories defined by the MEESSI score
Mortality rate [ Time Frame: 30 days ]30 daysMortality rate at 30 days compared between the 4 risk categories defined by the MEESSI score
Sensitivity [ Time Frame: 30 days ]30 daysSensitivity, specificity and ROC curve of the MEESSI score in relation to the composite criterion according to the 4 risk categories

Countries

Tunisia

Contacts

Primary ContactSemir Nouira, Professor
semir.nouira@rns.tn7310600
Backup ContactKhaoula Bel Haj Ali, MD
belhajalikhaoula@yahoo.fr7310600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026